121 related articles for article (PubMed ID: 32423281)
1. H
Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
[TBL] [Abstract][Full Text] [Related]
2. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
[TBL] [Abstract][Full Text] [Related]
3. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
[TBL] [Abstract][Full Text] [Related]
4. Establishment of H
Yamada S; Itai S; Nakamura T; Chang YW; Harada H; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):287-290. PubMed ID: 29172998
[TBL] [Abstract][Full Text] [Related]
5. An Anti-HER2 Monoclonal Antibody H
Tateyama N; Asano T; Ohishi T; Takei J; Hosono H; Nanamiya R; Tanaka T; Sano M; Saito M; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):184-190. PubMed ID: 34424760
[TBL] [Abstract][Full Text] [Related]
6. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Takei J; Nakamura T; Sano M; Asano T; Sayama Y; Hosono H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):123-128. PubMed ID: 32552424
[TBL] [Abstract][Full Text] [Related]
7. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer.
Kaneko MK; Yamada S; Itai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):59-62. PubMed ID: 29315012
[TBL] [Abstract][Full Text] [Related]
8. H
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
[TBL] [Abstract][Full Text] [Related]
9. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
[TBL] [Abstract][Full Text] [Related]
10. Defucosylated Monoclonal Antibody (H
Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
13. H
Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf).
Suzuki H; Asano T; Ohishi T; Yoshikawa T; Suzuki H; Mizuno T; Tanaka T; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):34-40. PubMed ID: 36383106
[TBL] [Abstract][Full Text] [Related]
16. Development of a Novel Anti-HER2 Monoclonal Antibody H
Takei J; Asano T; Tanaka T; Sano M; Hosono H; Nanamiya R; Tateyama N; Saito M; Suzuki H; Harada H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):168-176. PubMed ID: 34424764
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
[TBL] [Abstract][Full Text] [Related]
19. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
20. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
